期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 61, 期 7-8, 页码 623-632出版社
ELSEVIER
DOI: 10.1016/j.addr.2009.01.006
关键词
Hypoxia-inducible factor 1 (HIF-1); Tumor hypoxia; Gene therapy; Hypoxia-responsive element (HRE); Gene-Directed Enzyme Prodrug Therapy (GDEPT); Protein transduction domain (PTD); Bioluminescence; In vivo imaging
资金
- Ministry of Education, Culture, Sports, Science and Technology
Solid tumors possess unique microenvironments that are exposed to chronic hypoxic conditions, so-called tumor hypoxia. Although more than half a century has passed since it was suggested that tumor hypoxia correlated with bad treatment outcomes and contributed to the recurrence of cancer, no fundamental solution to this problem has yet been found. Hypoxia-inducible factor HIF-1 is the main transcription factor that regulates the cellular response to hypoxia. It induces various genes, whose function is strongly associated with the malignant alteration of the entire tumor. The cellular changes induced by HIF-1 are extremely important therapeutic targets of cancer therapy, particularly in the therapy against refractory cancers. Therefore targeting strategies to overcome the HIF-1-active microenvironment are important for cancer therapy. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据